A STUDY ON GLUTAMIC ACID DECARBOXYLASE 65 (GAD-65) AUTOANTIBODY AND ANTI-INSULIN AUTOANTIBODY IN LEAN PATIENTS WITH DIABETES MELLITUS

2016 ◽  
pp. 137-144
Author(s):  
Thi Minh Phuong Phan
Keyword(s):  
Glutamic Acid ◽  
Glutamic Acid Decarboxylase ◽  
Acid Decarboxylase ◽  
Diabetic Patients ◽  
Insulin Autoantibody ◽  
Significant Difference ◽  
Patients With Diabetes ◽  
Positive Rate ◽  
Gad 65 ◽  
Glutamic Acid Decarboxylase 65

Introduction and objectives: The Glutamic acid decarboxylase 65 (GAD-65) autoantibody and anti-insulin autoantibody (IAA) are serum markers of autoimmune diabetic patients. The presence of these autoantibodies in aging diabetic patients can differenciate the latent autoimmune diabetes in adults (LADA) from type 2 diabetes. Patients with these auto-antibodies were considered high risk group and will progress into insulin dependent in 5-7 years. This study was carried out with aims:(1) To define the positive rate, the concentration of GAD-65 autoantibody and IAA on lean patients with diabetes. (2) To survey the correlation between the presence of GAD-65 autoantibody, IAA and several clinical and laboratory characteristics of these patients. Objects and methods: 86 patients diagnosed of diabetes following the ADA 2015 criteria, fasting glucose ≥ 126 mg/dL (or ≥ 7.0 mmol/L) and HbA1C > 6.5%. Indirect ELISA technique was performed to measure anti GAD-65 autoantibody and IAA. Kits used in the study were AESKULISA GAD-65 from AESKU Company- Germany and IAA ELISA from DRG Company- Germany. Results: the positive rate with anti GAD-65 and IAA was 48.84% and 30.23% respectively. The positive rate with one of the two antibodies was 55.81%; the positive rate with both antibodies was 23.26%. Mean concentration of GAD-65 positive was 51.08 ± 16,86 IU/mL; The average concentration of IAA positive was 1,46 ± 0,27 U/mL. Regarding the correlation between the concentration of GAD-65, IAA and laboratory data: there is a statistically significant difference (p<0.05) between positive GAD-65 antibody and insulin concentration. A statistically significant difference between GAD-65 antibody and hypertriclyceridemia in the studied and control group (p<0.05) is also observed. Keywords: glutamic acid decarboxylase (GAD) autoantibody, insulin autoantibody, diabetes mellitus

scholarly journals Islet cell and glutamic acid decarboxylase-65 autoantibodies in young diabetic patients attending in a General Hospital in Dhaka City

2020 ◽  
Vol 46 (2) ◽  
pp. 104-108
Author(s):  
Ashesh Kumar Chowdhury ◽  
Shahjalalur Rahman Sahi ◽  
Mohammad Moniruzzaman ◽  
Mansura Khan
Keyword(s):  
Beta Cell ◽  
Diabetic Control ◽  
Acid Decarboxylase ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Significant Difference ◽  
Gad 65 ◽  
Glutamic Acid Decarboxylase 65 ◽  
Type 2 Diabetic

Background: Immune mediated destruction of pancreatic beta cell in type-I diabetes is well established but its’ role in young type-2 diabetic patients is still not conclusive. These young diabetic patients pass through several stages where they do not need insulin but found to have serum autoantibody against islets cell and even become dependent on insulin for survival in course of time. This study aims to find the presence of islets cell auto-antibodies (ICA) and autoantibody to glutamic acid decarboxylase-65 (GAD-65) in non-insulin requiring young diabetic patients of Bangladesh. Objective: To evaluate the presence of ICA and GAD-65 between the non-insulin requiring young type-2 diabetic patients and compare with the non-diabetic control group. Method: This case control study was carried out at the Department of Immunology, BIRDEM General Hospital, Dhaka for a period of one year from July 2013, A total of 120 non-insulin requiring (≥12 months) young type-2 diabetic patients and 60 age, sex matched non-diabetic were enrolled as control subjects following inclusion and exclusion criteria. ICA and GAD-65 tests were performed by enzyme linked immune-sorbent assay (ELISA) method by using kits from DRG Inc. International, USA. Results: In this study statistically significant difference found between non insulin requiring young diabetic patients and non diabetic control in respect of positive ICA result (p=0.015). The moderately strong negative association was found between different age of onset of diabetes mellitus and value of ICA level (r=-0.45). Only 20-24 years age group showed statistically significant difference between patient and control (p=0.013). Statistically significant difference was not found in GAD-65 values of non insulin requiring young diabetic patients and non diabetic controls (p=0.441). Conclusion: This study revealed that there is significant difference present in respect of ICA among non-insulin requiring young diabetic patients and non-diabetic controls. Therefore, autoimmune pathogenesis of beta cell killing by producing ICA against islets cell take place in young type-2 diabetic patients. Bangladesh Med Res Counc Bull 2020; 46(2): 104-108

scholarly journals Glutamic acid decarboxylase positivity in selected group of Bangladeshi type 2 diabetic patients

2019 ◽  
Vol 9 (3) ◽  
pp. 213-217
Author(s):  
Nazimul Islam ◽  
Tanjima Begum ◽  
Ashesh Kumar Chowdhury ◽  
Umarah Miazi ◽  
Md Soharab Alam ◽  
...  
Keyword(s):  
Glutamic Acid ◽  
Glutamic Acid Decarboxylase ◽  
Autoimmune Diabetes ◽  
Adult Patients ◽  
Acid Decarboxylase ◽  
Diabetic Patients ◽  
Newly Diagnosed ◽  
Type 2 Diabetic Patients ◽  
Significant Difference

Background: Many patients with type 2 diabetes mellitus (T2DM) test positive for glutamic acid decarboxylase (GAD).These individuals have been referred to as having latent autoimmune diabetes in adults (LADA) or type 1.5 diabetes. LADA refers to a specific type of diabetes affecting adult patients, characterized by presence of islet auto-antibodies, insulin independence at the time of diagnosis and characterized by slower beta cell destruction. The aim of this study was to indentify GAD positivity in a selected group of Bangladeshi T2DM patients and compare the clinical characteristics of GAD positive and negative subjects. Methods: This cross-sectional study was conducted in 2017 at BIRDEM General Hospital, Dhaka. Recently diagnosed drug-naive patients with T2DM were evaluated. Considering inclusion and exclusion criteria 100 subjects were screened. These patients allowed for the assessment of GAD positivity along with anthropometric and biochemical characteristics. Results: A total of 100 newly diagnosed (within 6 months) T2DM patients in age group 30-70 years were selected for this study. Of them men and women were 59.6% and 40.4% respectively. The GAD antibody positive was found to be 10%. There was no significant difference in respect of age, body mass index, fasting plasma glucose, HbA1c, total cholesterol, triglycerides, HDL cholesterol, LDL and blood pressure between GAD positive and GAD negative subjects. Conclusion: The presence of GAD positivity was 10% among adult patients with newly diagnosed T2DM which wasvery high in Bangladeshi population. Further long term prospective studies need to be essential to identify the actual situation of GAD positive subjects and to determine their clinical course and optimal treatment regimens. Birdem Med J 2019; 9(3): 213-217

scholarly journals Low rate of glutamic acid decarboxylase 65 (GAD-65) antibodies in chronic epilepsy

Seizure ◽  
2020 ◽  
Vol 80 ◽  
pp. 38-41
Author(s):  
Etsegenet Tizazu ◽  
Colin A. Ellis ◽  
Julia Reichert ◽  
Eric Lancaster
Keyword(s):  
Glutamic Acid ◽  
Glutamic Acid Decarboxylase ◽  
Acid Decarboxylase ◽  
Chronic Epilepsy ◽  
Gad 65 ◽  
Glutamic Acid Decarboxylase 65 ◽  
Gad 65 Antibodies ◽  
Low Rate

STUDY ON LEVEL OF ANTI GAD AND ICA AUTOANTIBODIES IN PATIENTSWITH DIABETES MELLITUS

2016 ◽  
pp. 78-85
Author(s):  
Thi Minh Phuong Phan ◽  
Dinh Thanh Truong
Keyword(s):  
Diabetes Mellitus ◽  
Statistical Significance ◽  
Enzyme Linked Immunosorbent Assay ◽  
Acid Decarboxylase ◽  
Diabetic Patients ◽  
Significant Difference ◽  
Patients With Diabetes ◽  
Positive Rate ◽  
The Difference ◽  
The One

Background: Autoantibodies anti GAD and ICA associated to the autoimmune process of patients with diabetes. Detection of these antibodies in progessive diabeticpatients is very necessary because the presence of anti GAD and ICA can predict the progression of the disease to insulin-dependent diabetes in the future. This study was carried out with aims: (1) to define the positive rate, anti GAD and ICA level in patients with diabetes. (2) to evaluate the correlation between anti GAD and ICA with several clinical and paraclinical features of diabetic patients. Materials and method: 88 patients diagnosed of diabetes by the criteria of ADA 2014, withfasting glucose ≥ 126 mg/dL or≥ 7,0 mmol/L) and HbA1C> 6.5%. Indirect enzyme linked immunosorbent assay (ELISA) was used to measure those autoantibodies of anti GAD and ICA, kits were supplied by DRG company, Germany. Results: the anti GAD positive rate was 10.2%; mean of level of anti GAD was 1.44±0.25 U/mL. ICA positive ratewas 9.1%; mean of level of ICA was 1.44±0.12 U/mL. Positive rate with anti GAD and/or ICA was 19.3%. About the correlation between level of anti GAD, ICA with some of clinical features, we found only the statistically significant difference with p<0.05 between blur vision in the group of ICA level > 1.25U/mL with group of ICA level< 1.25U/mL. About the paraclinical features, the difference with statistical significance (p<0.05) of HbA1C>6.5% was found between the group with anti GAD> 1.05U/mLand the one with anti GAD< 1.00U/mLand also betweenthe group of ICA > 1.25 U/mL and ICA < 1.25 U/mL. Key words: autoantibody anti glutamic acid decarboxylase, islet cell autoantibodies, diabetes mellitus.

Peptide specificity of high-titer anti-glutamic acid decarboxylase (GAD)65 autoantibodies

1998 ◽  
Vol 62 (3) ◽  
pp. 123-130 ◽  
Author(s):  
Faı̈za Rharbaoui ◽  
Claude Granier ◽  
Mouna Kellou ◽  
Jean-Claude Mani ◽  
Peter van Endert ◽  
...  
Keyword(s):  
Glutamic Acid ◽  
Glutamic Acid Decarboxylase ◽  
High Titer ◽  
Acid Decarboxylase ◽  
Peptide Specificity ◽  
Gad 65
Sign in / Sign up

Export Citation Format

Share Document